Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00126451
Status:
TERMINATED
Last Update Posted:
2017-04-10
First Post:
2005-08-02
Brief Title:
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid SAHA in Patients With Relapsed or Refractory Breast Colorectal and Non-Small Cell Lung Cancer 0683-011TERMINATED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase II Clinical Study of Oral Suberoylanilide Hydroxamic Acid in Patients With Relapsed or Refractory Breast Colorectal and Non-small Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an investigational study to determine the response rate of relapsedrefractory breast colorectal and non-small cell lung cancer to oral suberoylanilide hydroxamic acid SAHA to evaluate PET as an earlier indicator of response to SAHA as assessed by response evaluation criteria in solid tumours RECIST criteria and to evaluate the safety and tolerability of oral suberoylanilide hydroxamic acid
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_014 | None | None | None |